Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 13Phase 1 13Phase 2/3 5Phase 1/2 5Phase NA 3Phase EARLY_PHASE1 3

Status

Recruiting 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 1Carcinoma, Hepatocellular 1CRC 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Folfox protocol × 1 year × Clear all
NCT06598007 2026-05-29

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

Crossignal Therapeutics, Inc.

Phase 1/2 Recruiting
78 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04068610 2026-05-15

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

MedImmune LLC

Phase 1/2 Active not recruiting
61 enrolled 35 charts
Gastrointestinal

Colonic Neoplasms

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Tongji Hospital

Phase 1/2 Not yet recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

NCT06936527 2025-09-03

XS-03-II201

NovaOnco Therapeutics Co., Ltd.

Phase 1/2 Enrolling by invitation
102 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡